A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

BACKGROUND To define better the efficacy of vasodilator therapy in the treatment of chronic congestive heart failure, we compared the effects of hydralazine and isosorbide dinitrate with those of enalapril in 804 men receiving digoxin and diuretic therapy for heart failure. The patients were randomly assigned in a double-blind manner to receive 20 mg of enalapril daily or 300 mg of hydralazine plus 160 mg of isosorbide dinitrate daily. The latter regimen was identical to that used with a similar patient population in the effective-treatment arm of our previous Vasodilator-Heart Failure Trial. RESULTS Mortality after two years was significantly lower in the enalapril arm (18 percent) than in the hydralazine-isosorbide dinitrate arm (25 percent) (P = 0.016; reduction in mortality, 28.0 percent), and overall mortality tended to be lower (P = 0.08). The lower mortality in the enalapril arm was attributable to a reduction in the incidence of sudden death, and this beneficial effect was more prominent in patients with less severe symptoms (New York Heart Association class I or II). In contrast, body oxygen consumption at peak exercise was increased only by hydralazine-isosorbide dinitrate treatment (P less than 0.05), and left ventricular ejection fraction, which increased with both regimens during the 2 years after randomization, increased more (P less than 0.05) during the first 13 weeks in the hydralazine-isosorbide dinitrate group. CONCLUSIONS The similar two-year mortality in the hydralazine-isosorbide dinitrate arms in our previous Vasodilator-Heart Failure Trial (26 percent) and in the present trial (25 percent), as compared with that in the placebo arm in the previous trial, (34 percent) and the further survival benefit with enalapril in the present trial (18 percent) strengthen the conclusion that vasodilator therapy should be included in the standard treatment for heart failure. The different effects of the two regimens (enalapril and hydralazine-isosorbide dinitrate) on mortality and physiologic end points suggest that the profile of effects might be enhanced if the regimens were used in combination.

[1]  R. Cody.  Clinical and hemodynamic experience with enalapril in congestive heart failure. , 1985, The American journal of cardiology.

[2]  M. Packer,et al.  Comparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. , 1986, The American journal of cardiology.

[3]  W. Parmley,et al.  The role of vasodilator therapy in heart failure. , 1977, Progress in cardiovascular diseases.

[4]  J. Cohn,et al.  Current therapy of the failing heart. , 1988, Circulation.

[5]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[6]  J. Cohn.  Vasodilator Therapy for Heart Failure: The Influence of Impedance on Left Ventricular Performance , 1973, Circulation.

[7]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[8]  J. Cohn,et al.  Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside. , 1978, Chest.

[9]  T. Ryan,et al.  Acute and long-term effects of enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure. , 1985, Journal of the American College of Cardiology.

[10]  J. Cohn,et al.  Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. , 1980, The American journal of medicine.

[11]  G. Francis.  Heart failure management: the impact of drug therapy on survival. , 1988, American heart journal.

[12]  J. Cohn,et al.  Vasodilator Therapy of Cardiac Failure , 1977 .

[13]  R. Magorien,et al.  Improved Exercise Capacity and Differing Arterial and Venous Tolerance During Chronic Isosorbide Dinitrate Therapy for Congestive Heart Failure , 1983, Circulation.

[14]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[15]  J. Cohn,et al.  Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure. , 1984, Circulation.